This review investigates cotinine, a non-toxic metabolite of nicotine, as a potential treatment for Alzheimer's disease (AD). Preclinical studies have shown that cotinine enhances memory, reduces amyloid-beta (Aβ) pathology, and mitigates tau-related neurotoxicity in animal models. Mechanistically, cotinine appears to modulate α7 nicotinic acetylcholine receptors (α7nAChRs), activate the Akt signaling
